JaxBio Technologies
Developing a Blood Test for Early Cancer Diagnosis
Company Overview
Snapshot
Founded in January 2022 by Shahar Zirkin, Joel Bar-El, Dror Feldheim, and Yuval Ebenstein, JaxBio Technologies operates with 11–50 employees. The company has secured funding across 2 rounds, with a notable grant from the European Innovation Council (EIC) Accelerator in July 2024.
Business overview
JaxBio Technologies is a medical diagnostics company focused on transforming cancer diagnosis and management through a sensitive blood test. The company's core technology involves an ultra-sensitive method to detect genetic and epigenetic profiles in cell-free DNA, which are indicative of cancer initiation and progression. By extracting cell-free DNA from blood samples and utilizing a proprietary fluorescent labeling process, JaxBio develops custom chips that reveal unique pixel pattern signatures for classifying cancer type and stage. The company currently targets the early detection and monitoring of lung cancer and hematological malignancies, serving the broader healthcare and life sciences sectors.
Strategic signal
In July 2024, JaxBio Technologies secured a €2.5M grant from the European Innovation Council (EIC) Accelerator, with an option for an additional €9.1M in blended financing. This significant non-dilutive funding validates the potential of JaxBio's diagnostics platform and provides crucial capital to expand clinical programs, particularly for lung cancer detection. For investors, this signals strong institutional backing and accelerated development towards commercialization in a high-demand market.
Log in to access full profile ›Company Intelligence Q&A
- What is JaxBio Technologies' primary focus?
- JaxBio Technologies is focused on developing a simple and sensitive blood test for the early detection, monitoring, and prediction of therapy response for various cancers, initially targeting lung cancer and hematological malignancies.
- When was JaxBio Technologies founded and by whom?
- JaxBio Technologies was founded in January 2022 by Shahar Zirkin, Joel Bar-El, Dror Feldheim, and Yuval Ebenstein.
- What significant grant did JaxBio Technologies receive in July 2024?
- In July 2024, JaxBio Technologies secured a €2.5M grant from the.
- What technology does JaxBio Technologies utilize for cancer detection?
- JaxBio Technologies uses an ultra-sensitive method to detect genetic and epigenetic profiles in cell-free DNA from blood samples. This involves fluorescently labeling markers and hybridizing the DNA onto a custom chip to identify unique pixel pattern signatures for cancer classification.
- What was the purpose of the EU Horizon Europe grant received in January 2023?
- In January 2023, JaxBio Technologies received an EU Horizon Europe grant to support the development of an array-based platform for diagnosing hematological malignancies, specifically to create a liquid biopsy-based test called Sanguine that detects epigenetic markers using a custom microarray (HemaChip).